Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
A recent ovarian cancer genome-wide association study (GWAS) identified a locus on 9p22 associated with reduced ovarian cancer risk. The single nucleotide polymorphism (SNP) markers localize to the BNC2 gene, which has been associated with ovarian development.We analyzed the association of 9p22 SNPs...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3131287?pdf=render |
| _version_ | 1828342491021049856 |
|---|---|
| author | Nicolas Wentzensen Amanda Black Kevin Jacobs Hannah P Yang Christine D Berg Neil Caporaso Ulrike Peters Lawrence Ragard Saundra S Buys Stephen Chanock Patricia Hartge |
| author_facet | Nicolas Wentzensen Amanda Black Kevin Jacobs Hannah P Yang Christine D Berg Neil Caporaso Ulrike Peters Lawrence Ragard Saundra S Buys Stephen Chanock Patricia Hartge |
| author_sort | Nicolas Wentzensen |
| collection | DOAJ |
| description | A recent ovarian cancer genome-wide association study (GWAS) identified a locus on 9p22 associated with reduced ovarian cancer risk. The single nucleotide polymorphism (SNP) markers localize to the BNC2 gene, which has been associated with ovarian development.We analyzed the association of 9p22 SNPs with transvaginal ultrasound (TVU) screening results and CA-125 blood levels from participants without ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO); 1,106 women with adequate ultrasound screening results and available genotyping information were included in the study.We observed a significantly increased risk of abnormal suspicious TVU results for seven SNPs on 9p22, with odds ratios between 1.68 (95% CI: 1.04-2.72) for rs4961501 and 2.10 (95% CI: 1.31-3.38) for rs12379183. Associations were restricted to abnormal suspicious findings at the first TVU screen. We did not observe an association between 9p22 SNPs and CA-125 levels.Our findings suggest that 9p22 SNPs, which were found to be associated with decreased risk of ovarian cancer in a recent GWAS, are associated with sonographically detectable ovarian abnormalities. Our results corroborate the relevance of the 9p22 locus for ovarian biology. Further studies are required to understand the complex relationship between screening abnormalities and ovarian carcinogenesis and to evaluate whether this locus can influence the risk stratification of ovarian cancer screening. |
| first_indexed | 2024-04-13T23:30:28Z |
| format | Article |
| id | doaj.art-3047cc10296d46859a661109d98c0492 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T23:30:28Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3047cc10296d46859a661109d98c04922022-12-22T02:24:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0167e2173110.1371/journal.pone.0021731Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Nicolas WentzensenAmanda BlackKevin JacobsHannah P YangChristine D BergNeil CaporasoUlrike PetersLawrence RagardSaundra S BuysStephen ChanockPatricia HartgeA recent ovarian cancer genome-wide association study (GWAS) identified a locus on 9p22 associated with reduced ovarian cancer risk. The single nucleotide polymorphism (SNP) markers localize to the BNC2 gene, which has been associated with ovarian development.We analyzed the association of 9p22 SNPs with transvaginal ultrasound (TVU) screening results and CA-125 blood levels from participants without ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO); 1,106 women with adequate ultrasound screening results and available genotyping information were included in the study.We observed a significantly increased risk of abnormal suspicious TVU results for seven SNPs on 9p22, with odds ratios between 1.68 (95% CI: 1.04-2.72) for rs4961501 and 2.10 (95% CI: 1.31-3.38) for rs12379183. Associations were restricted to abnormal suspicious findings at the first TVU screen. We did not observe an association between 9p22 SNPs and CA-125 levels.Our findings suggest that 9p22 SNPs, which were found to be associated with decreased risk of ovarian cancer in a recent GWAS, are associated with sonographically detectable ovarian abnormalities. Our results corroborate the relevance of the 9p22 locus for ovarian biology. Further studies are required to understand the complex relationship between screening abnormalities and ovarian carcinogenesis and to evaluate whether this locus can influence the risk stratification of ovarian cancer screening.http://europepmc.org/articles/PMC3131287?pdf=render |
| spellingShingle | Nicolas Wentzensen Amanda Black Kevin Jacobs Hannah P Yang Christine D Berg Neil Caporaso Ulrike Peters Lawrence Ragard Saundra S Buys Stephen Chanock Patricia Hartge Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PLoS ONE |
| title | Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
| title_full | Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
| title_fullStr | Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
| title_full_unstemmed | Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
| title_short | Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. |
| title_sort | genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the prostate lung colorectal and ovarian cancer screening trial |
| url | http://europepmc.org/articles/PMC3131287?pdf=render |
| work_keys_str_mv | AT nicolaswentzensen geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT amandablack geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT kevinjacobs geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT hannahpyang geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT christinedberg geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT neilcaporaso geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT ulrikepeters geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT lawrenceragard geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT saundrasbuys geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT stephenchanock geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial AT patriciahartge geneticvariationon9p22isassociatedwithabnormalovarianultrasoundresultsintheprostatelungcolorectalandovariancancerscreeningtrial |